Wednesday, 19 April 2017

AbbVie cancer drug fails two late-stage trials

(Reuters) - AbbVie Inc said on Wednesday that its cancer drug, veliparib, failed to meet the main goals of two late-stage studies.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)